OTC labeling reform: NDMA opposes "all caps" warnings in meeting with FDA.
This article was originally published in The Tan Sheet
OTC LABELING REFORM: NDMA OPPOSED TO REQUIRING ALL CAPITAL LETTERS in warning statements, Nonprescription Drug Manufacturers Association Senior VP-Science & Technology William Soller, PhD, told FDA officials at a Jan. 30 "OTC feedback" meeting. "There are other ways" to display information prominently, Soller said. He suggested that FDA "can get around" using all caps "by trying...color or all-bold" lettering.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC